APA (7th ed.) Citation

Morelli, M., Scarponi, C., Mercurio, L., Facchiano, F., Pallotta, S., Madonna, S., . . . Albanesi, C. Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis. Wiley.

Chicago Style (17th ed.) Citation

Morelli, Martina, Claudia Scarponi, Laura Mercurio, Francesco Facchiano, Sabatino Pallotta, Stefania Madonna, Giampiero Girolomoni, and Cristina Albanesi. Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis. Wiley.

MLA (9th ed.) Citation

Morelli, Martina, et al. Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis. Wiley.